EDIT has been granted a new patent
Dec 25, 2024, 11:36 PM
16.53%
What does EDIT do
Editas Medicine, headquartered in Cambridge, Massachusetts, specializes in genome editing technology and developed a proprietary CRISPR-based platform for transformative genomic medicines. Its lead program, reni-cel, aims to treat sickle cell disease and beta thalassemia.
EDIT filed a patent for "systems and methods for the treatment of hemoglobinopathies" on Fri, January 27, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.